European Journal of Clinical Pharmacology

, Volume 68, Issue 11, pp 1533–1540

Non-steroidal anti-inflammatory drugs (NSAIDs) and hypertension treatment intensification: a population-based cohort study

Authors

    • Laboratoire de Pharmacologie Médicale et Clinique, Faculté de MédecineUniversité Paul Sabatier
    • INSERM, UMR1027
    • Département Universitaire de Médecine Générale, Faculté de MédecineUniversité Paul Sabatier
  • Agnès Sommet
    • Laboratoire de Pharmacologie Médicale et Clinique, Faculté de MédecineUniversité Paul Sabatier
    • INSERM, UMR1027
    • Service de Pharmacologie Clinique, Centre Midi-Pyrénées de Pharmacovigilance, de Pharmacoépidémiologie et d’Information sur le MédicamentCentre Hospitalier Universitaire de Toulouse
  • Robert Bourrel
    • Direction Régionale du Service Médical Midi-Pyrénées (CNAMTS)
  • Stéphane Oustric
    • Département Universitaire de Médecine Générale, Faculté de MédecineUniversité Paul Sabatier
  • Atul Pathak
    • Laboratoire de Pharmacologie Médicale et Clinique, Faculté de MédecineUniversité Paul Sabatier
    • Service de Pharmacologie Clinique, Centre Midi-Pyrénées de Pharmacovigilance, de Pharmacoépidémiologie et d’Information sur le MédicamentCentre Hospitalier Universitaire de Toulouse
    • INSERM UMR1048
  • Maryse Lapeyre-Mestre
    • Laboratoire de Pharmacologie Médicale et Clinique, Faculté de MédecineUniversité Paul Sabatier
    • INSERM, UMR1027
    • Service de Pharmacologie Clinique, Centre Midi-Pyrénées de Pharmacovigilance, de Pharmacoépidémiologie et d’Information sur le MédicamentCentre Hospitalier Universitaire de Toulouse
  • Jean-Louis Montastruc
    • Laboratoire de Pharmacologie Médicale et Clinique, Faculté de MédecineUniversité Paul Sabatier
    • INSERM, UMR1027
    • Service de Pharmacologie Clinique, Centre Midi-Pyrénées de Pharmacovigilance, de Pharmacoépidémiologie et d’Information sur le MédicamentCentre Hospitalier Universitaire de Toulouse
Pharmacoepidemiology and Prescription

DOI: 10.1007/s00228-012-1283-9

Cite this article as:
Fournier, J., Sommet, A., Bourrel, R. et al. Eur J Clin Pharmacol (2012) 68: 1533. doi:10.1007/s00228-012-1283-9

Abstract

Purpose

Non-steroidal anti-inflammatory drugs (NSAIDs) are known to antagonize the effects of antihypertensive drugs, and these associations can lead to an increase in arterial blood pressure. However, the impact of NSAIDs on hypertension treatment management in large-scale populations remains poorly evaluated. We examined whether the introduction of NSAID into the treatment regimen would induce an intensification of hypertension treatment (defined as the introduction of a new antihypertensive drug).

Methods

We conducted a cohort study involving 5,710 hypertensive subjects included in the French health insurance system database who had been treated and stabilized with their antihypertensive therapy and not exposed to any NSAID between 1 April 2005 and 1 April 2006. The maximum follow-up duration was 4 years.

Results

Adjusted hazard ratios (HR) for hypertension treatment intensification were 1.34 [95 % confidence interval (CI) 1.05–1.71] for NSAIDs in general, 1.79 (95 % CI 1.15–2.78) for diclofenac and 2.02 (95 % CI:1.09–3.77) for piroxicam. There were significant interactions between NSAIDs and angiotensin converting enzyme inhibitors (ACEIs; HR  4.09, 95 % CI 2.02–8.27) or angiotensin receptor blockers (ARBs; HR 3.62, 95 % CI 1.80–7.31), but not with other antihypertensive drugs.

Conclusions

Exposure to NSAIDs leads to an intensification of hypertension treatment, especially in patients treated with ACEIs or ARBs. Renin–angiotensin system blockers should be avoided whenever NSAIDs are prescribed.

Keywords

Anti-inflammatory agents, non-steroidal Antihypertensive agents Cohort studies Drug interactions Insurance, health, reimbursement Pharmacoepidemiology

Copyright information

© Springer-Verlag 2012